Provided by Tiger Fintech (Singapore) Pte. Ltd.

Artivion

30.48
-0.1090-0.36%
Volume:150.92K
Turnover:4.60M
Market Cap:1.43B
PE:-57.51
High:30.72
Open:30.60
Low:30.32
Close:30.58
Loading ...

Stock Track | Artivion Plunges 7.43% as Investors Digest Cybersecurity Impact

Stock Track
·
25 Feb

Artivion Is Maintained at Buy by Needham

Dow Jones
·
25 Feb

Artivion Inc : Stifel Cuts Target Price to $30 From $33

THOMSON REUTERS
·
25 Feb

Artivion’s Resilient Growth Potential: Overcoming Cybersecurity Setbacks with Strong Fundamentals and New Developments

TIPRANKS
·
25 Feb

Artivion (AORT) Reports Break-Even Earnings for Q4

Zacks
·
25 Feb

Stock Track | Artivion Plunges 6.64% After-Hours on Disappointing Q4 Results

Stock Track
·
25 Feb

Artivion Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Artivion Q4 Adj EPS $0 Miss $-0.06 Estimate, Sales $97.31M Miss $100.82M Estimate

Benzinga
·
25 Feb

BRIEF-Artivion Q4 Revenue USD 97.308 Million Vs. IBES Estimate USD 100.8 Million

Reuters
·
25 Feb

Artivion Q4 Pretax Profit USD -16.602 Million

THOMSON REUTERS
·
25 Feb

Artivion Inc: Expects Adj Ebitda Growth of Between 18% and 28% for Full Year 2025 Compared to 2024

THOMSON REUTERS
·
25 Feb

Should You Investigate Artivion, Inc. (NYSE:AORT) At US$28.26?

Simply Wall St.
·
25 Feb

Artivion Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
22 Feb

Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack

StockStory
·
14 Feb

Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3

StockStory
·
13 Feb

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

PR Newswire
·
11 Feb

Sensus Healthcare (SRTS) Moves 19.9% Higher: Will This Strength Last?

Zacks
·
03 Feb

Artivion Receives Buy Rating from Michael Matson Following Promising Clinical Trial Results and Market Expansion Opportunities

TIPRANKS
·
28 Jan

Positive Trial Data and FDA Prospects Drive Buy Rating for Artivion

TIPRANKS
·
28 Jan

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

PR Newswire
·
27 Jan